search
Back to results

Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

Primary Purpose

Cervical Cancer

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Topotecan
Cisplatin
Sponsored by
University of New Mexico
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Cancer focused on measuring Cancer, Cervix

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Patients with histologically confirmed advanced cervical carcinoma who, following optional surgical staging, are not deemed to be curable by either surgery or radiotherapy alone. This includes patients with stages IIB, IIIA, IIIB or IVA and stages IB or IIA who in addition have one of the following risk factors: Primary tumor > 6 cm Positive pelvic and/or para-aortic lymph nodes (resected or unresected) Positive surgical margins Depth of invasion greater than 50 % and positive capillary-lymphatic space involvement Eligible cell types include squamous, adenosquamous and adenocarcinoma of the cervix Patients may have measurable disease (defined as lesions which can be measured in at least two (2) dimensions by physical examination or any medical imaging technique). Inability to measure disease will not constitute exclusion criteria. Patients with GOG performance status of 0, 1, or 2. Patients will have recovered from the effects of recent surgery and should be free of clinically significant infection. Patients must have adequate: Bone marrow function: WBC greater than or equal to 3,000 cells/mm3, platelet count greater than or equal to 100,000 cells/mm3, and granulocyte count greater than or equal to 1,500 cells/mm3. Renal function: Creatinine less than or equal to 2.0 mg/dl. Hepatic function: Bilirubin less than or equal to 1.5 x institutional normal, SGOT and alkaline phosphatase less than or equal to 3 x institutional normal. Patients must have signed an approved informed consent. Patients have met the pre-entry requirements specified in Section 7.0 Exclusion Criteria: Patients with GOG performance of 3 or 4. Patients with another malignancy, prior or concomitant, other than skin (excluding melanoma). Patients with septicemia, severe infection, gastrointestinal bleeding, or intestinal obstruction. Patients with anatomic abnormalities requiring modification of radiation fields (pelvic kidney, renal transplant, etc.). Patient with recurrent cervical cancer Patients who have received prior pelvic radiation Pregnant women and women of childbearing potential not using an effective form of contraception. History of thrombus (10/28/02) History of unstable angina or MI within the past six months. Patients with evidence of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if their disease has been stable for the past six months. (10/28/02)

Sites / Locations

  • University of New Mexico

Outcomes

Primary Outcome Measures

disease progression

Secondary Outcome Measures

Full Information

First Posted
May 1, 2006
Last Updated
January 6, 2010
Sponsor
University of New Mexico
search

1. Study Identification

Unique Protocol Identification Number
NCT00320983
Brief Title
Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
Official Title
A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2008
Overall Recruitment Status
Completed
Study Start Date
March 2002 (undefined)
Primary Completion Date
June 2004 (Actual)
Study Completion Date
December 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of New Mexico

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Phase I Study of Adjuvant Topotecan and Cisplatin with Concurrent Radiation Therapy for Advanced Cervical Cancer.
Detailed Description
Examines the effects of Topotecan and Cisplatin with radiation for advanced cervical cancer

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer
Keywords
Cancer, Cervix

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Topotecan
Other Intervention Name(s)
Hycamtin
Intervention Description
Topotecan
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Other Intervention Name(s)
Platinol AQ
Intervention Description
Cisplatin
Primary Outcome Measure Information:
Title
disease progression
Time Frame
disease progress or complete remission

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with histologically confirmed advanced cervical carcinoma who, following optional surgical staging, are not deemed to be curable by either surgery or radiotherapy alone. This includes patients with stages IIB, IIIA, IIIB or IVA and stages IB or IIA who in addition have one of the following risk factors: Primary tumor > 6 cm Positive pelvic and/or para-aortic lymph nodes (resected or unresected) Positive surgical margins Depth of invasion greater than 50 % and positive capillary-lymphatic space involvement Eligible cell types include squamous, adenosquamous and adenocarcinoma of the cervix Patients may have measurable disease (defined as lesions which can be measured in at least two (2) dimensions by physical examination or any medical imaging technique). Inability to measure disease will not constitute exclusion criteria. Patients with GOG performance status of 0, 1, or 2. Patients will have recovered from the effects of recent surgery and should be free of clinically significant infection. Patients must have adequate: Bone marrow function: WBC greater than or equal to 3,000 cells/mm3, platelet count greater than or equal to 100,000 cells/mm3, and granulocyte count greater than or equal to 1,500 cells/mm3. Renal function: Creatinine less than or equal to 2.0 mg/dl. Hepatic function: Bilirubin less than or equal to 1.5 x institutional normal, SGOT and alkaline phosphatase less than or equal to 3 x institutional normal. Patients must have signed an approved informed consent. Patients have met the pre-entry requirements specified in Section 7.0 Exclusion Criteria: Patients with GOG performance of 3 or 4. Patients with another malignancy, prior or concomitant, other than skin (excluding melanoma). Patients with septicemia, severe infection, gastrointestinal bleeding, or intestinal obstruction. Patients with anatomic abnormalities requiring modification of radiation fields (pelvic kidney, renal transplant, etc.). Patient with recurrent cervical cancer Patients who have received prior pelvic radiation Pregnant women and women of childbearing potential not using an effective form of contraception. History of thrombus (10/28/02) History of unstable angina or MI within the past six months. Patients with evidence of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if their disease has been stable for the past six months. (10/28/02)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harriet Smith, MD
Organizational Affiliation
University of New Mexico
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of New Mexico
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

We'll reach out to this number within 24 hrs